Gene therapy-induced expression of immunostimulatory molecules at tumor cell level may evoke antitumor immune mechanisms by recruiting and enhancing viability of antigen-processing cells and specific tumoricidal lymphocytes. The antitumor efficacy of a plasmid, coding for granulocyte-macrophage colony-stimulating factor (GM-CSF) and the B7-1 costimulatory immune molecule, delivered into growing solid tumors by electroporation was investigated. Murine fibrosarcomas (JBS) growing in Balb/C mice (p100 mm 3 ) were transfected with GM-CSF/B7-1-expressing plasmid. Complete tumor regression occurred in greater than 60% of treated animals. This response was systemic, durable and tumor specific, with all responding animals resistant to repeat tumor challenge. Using a liver metastatic model, effective cure of distal metastases was achieved following treatment of the primary subcutaneous tumor. This treatment strategy could be applicable in the clinical setting for effective elimination of both primary tumors and associated metastatic disease.
Introduction
Since the discovery that immunostimulation reduces tumor growth, research has sought to prime the immune system to target tumor cell antigens as a therapeutic strategy. Tumor cell antigen presentation in the absence of costimulation is likely to induce anergy. 1, 2 Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to stimulate in vitro growth, maturation and function of antigen-presenting cells (APCs) such as dendritic cells and macrophages, and to augment tumorantigen presentation by recruited host APCs. [2] [3] [4] Experiments using genetically modified tumor cell vaccines revealed the potent ability of this cytokine to enhance antitumor immunity. 3 A recent phase I/II trial showed a dose-dependant efficacy of GM-CSF in the treatment of non-small-cell lung carcinoma with significantly prolonged survival in patients receiving vaccines secreting GM-CSF at more than 40 ng/24 h per 10 6 cells. 4 Other groups have examined the in vivo effects of coexpression of immune stimulatory molecules such as interleukin-2 (IL-2), GM-CSF and CD80 in various murine tumor models, with immune peptides either being expressed in vivo from genes, or by direct delivery of pharmaceutically derived molecules. 2, [5] [6] [7] [8] [9] The B7-1 (CD80) costimulatory molecule is usually expressed on the membrane of professional APCs, such as dendritic cells or B cells, initially binding to CD28 on CD4 þ (helper) T cells, and subsequently acting as a second signal following antigen-TCR engagement. 10, 11 Tumor cells usually lack expression of CD80 and without this costimulatory signal, T cells may become clonally anergic when the TCR signal is delivered.
11 B7-1-transduced tumor cells are expected to present both the antigen (TCR receptor) and the costimulatory (CD28-mediated) signals to CD8 þ cytotoxic T lymphocytes (CTLs) simultaneously, leading to efficient activation of CTLs without requiring the assistance of CD4 þ helper T cells. Transfection with B7-1 has already resulted in tumor cell rejection in several tumor models. 1, [12] [13] [14] [15] [16] The antitumor immunity induced by B7-1-transduced tumor cells was found to depend on the inherent antigenicity of the tumor. 14 Unmethylated CpG dinucleotide motifs found in DNA of bacterial origin, including plasmids, induce immune responses via the stimulation of Toll-like receptors on leukocytes. 17 CpG sequences stimulate Th1-biased proinflammatory immune responses characterized by cytokine release and activation of both the innate and adaptive immune systems. Although these effects can often limit the utility of gene therapy efforts, in applications such as vaccination and cancer immunotherapy plasmid DNA CpG-mediated stimulation of the immune system may be beneficial.
We hypothesized that a CpG-rich plasmid coding for the combination of GM-CSF and B7-1 might augment the immune system antitumor response by recruiting more APCs to the site of the tumors with subsequent antigen presentation as well as costimulatory signals (via the CD28 receptor) by the B7-1-transduced tumor cell. This would activate the CD8 þ CTLs without requiring the assistance of CD4 þ T cells. As a means of delivery of this plasmid to tumors, we assessed the use of electroporation utilizing intratumoral needle electrodes. We describe the transfection of growing murine tumors with a bicistronic plasmid construct expressing CD80 and GM-CSF using electroporation-mediated delivery. We report on the efficacy of local delivery of this plasmid in eradicating treated as well as distal tumors in a murine fibrosarcoma model.
Materials and methods

Cell tissue culture
Tumor cell lines were produced in the lab and grown in culture at 371C in a humidified atmosphere of 5% CO 2 , in Dulbecco's modified essential medium (DMEM; GIBCO, Invitrogen Corp., Paisley, Scotland) supplemented with 10% iron-supplemented donor calf serum, 50 mg/ml gentamycin, 300 mg/ml L-glutamine and 10 mM HEPES (1-piperazineethane sulfonic acid, 4-(2-hydroxyethyl) monosodium salt), pH 7.4. Tumor cells were dislodged from the surface of the flasks by first removing the tissue culture medium and washing the cells with an equal volume of phosphate-buffered saline (PBS). Cells were then treated with 0.05% w/v trypsin þ 0.02% w/v EDTA (ethylenediaminetetraacetic acid) in PBS and incubated for 2 min until cells became rounded and readily dislodged from the flask surface. Tissue culture medium was added to the harvested cells, and the cell suspensions were centrifuged at 180 g for 5 min. The cell pellets were then resuspended in the appropriate tissue culture medium, and the cell densities of the resulting cell suspensions were determined by visual count using a hemocytometer.
Viable cell counts were conducted by using Trypan blue dye exclusion (Sigma, Dublin, Ireland).
The cell lines used were the murine fibrosarcoma JBS and the murine colonic adenocarcinoma CT26. 18 JBS is a negative variant for the large T antigen and was derived from the simian virus 40 (SV40)-transformed 3T3 cell line in our laboratory by Dr John Barrett. 19 The SV40 3T3 cell line is tumorigenic only in immunocompromised mice, for example, MF1 athymic nude mice, and not in the immunocompetent syngeneic Balb/C animal. The JBS cell line was developed from a tumor that occurred spontaneously in one of a panel of Balb/C mice that were inoculated with SV403T3 cells in doses equivalent to those found to be tumorigenic in the athymic mouse. JBS is tumorigenic and classically MHC restricted to the Balb/C mouse. This tumor grows in immunocompetent Balb/C at the same rate as in athymic nude mice. 19 Vaccination strategies, using a diversity of approaches, schedules and cell treatments, failed to protect Balb/C mice from subsequent tumorigenic JBS challenges (Table 1) . Thus, this cell is considered weakly or non-immunogenic. We have demonstrated JBS cells to be both MHCI and Fas ligand positive (data not shown).
Plasmid construction
The mammalian expression vector pMG was purchased from Invivogen (Cayla SAS, Toulouse, France). A version of this plasmid, designated pGT141, containing the murine GM-CSF and human B7-1 genes transcriptionally controlled from the hEF1-HTLV and CMV promoters respectively was designed and cloning was performed on contract by Invivogen (Figure 1 ). Human B7-1 cDNA has been shown previously to function in a murine setting. 20 In order to construct a plasmid expressing only murine GM-CSF, the mouse GM-CSF gene was excised from pGT141 and subsequently cloned into the SgrAI-NheI sites of pMG downstream of the hEF1-HTLV promoter. A corresponding plasmid coding only for B7-1 was generated by deleting the GM-CSF gene from pGT141, which was achieved by the excision of DNA between the SgrAI-NheI restriction endonuclease sites (corresponding to the GM-CSF gene), followed by blunt-end ligation. The inserts were confirmed by sequencing. Plasmids were then In vitro cell transfection and generation of stable cell lines Plasmids were introduced into cells via electroporation as follows: cell concentrations of 1 Â 10 6 /ml were prepared in 100 ml of tissue culture medium (DMEM) and 10 mg plasmid DNA added. The cell/DNA suspension was placed in an electroporation cuvette of 1 mm gap distance (BTX Instruments, Harvard Apparatus Kent, UK) and the electric pulses were applied using an electropulsator ECM 2001 (BTX Inc., San Diego, CA). Stable transfectant clones were generated following selection with 200 mg/ml hygromycin B (Invivogen) and two rounds of limiting dilution cloning. Cloned transfectants were maintained in continuous culture for less than 3 months. A JBS clone stable for pGT141 was generated in this manner and designated JBS141. As a control, JBS was also stably transfected with pMG and the resultant clone termed JBSMG. In vitro cell doubling times were calculated using the CyQUANT Cell Proliferation Assay Kit (Invitrogen, BioSciences Ltd, Dublin, Ireland). The expression of B7-1 or GM-CSF from cells was analyzed by flow cytometry or ELISA as described. At least 85% of the cells were confirmed to express CD80 before transplantation.
Animals and tumor induction
Mice were obtained from Harlan Laboratories (Oxfordshire, England). They were kept at a constant room temperature (221C) with a natural day/night light cycle in a conventional animal colony. Standard laboratory food and water were provided ad libitum. Before experiments, the mice were afforded an adaptation period of at least 14 days. Female mice in good condition, without fungal or other infections, weighing 16-22 g and of 6-8 weeks of age, were included in experiments. For routine tumor induction, 2 Â 10 6 (JBS) or 5 Â 10 4 (CT26) tumor cells, suspended in 200 ml of a 50/50 dilution of DMEM in PBS (Sigma), were injected subcutaneously (s.c.) into the flank of female Balb/C or MF1-nu/nu mice. The viability of the cells used for inoculation was over 95% as determined by the Trypan blue dye exclusion test. Following tumor establishment, tumors were allowed to grow and develop and were monitored mostly by alternate day measurements in two dimensions using a verniers callipers. Tumor volume was calculated according to the formula V ¼ ab 2 P/6, where a is the longest diameter of the tumor and b is the longest diameter perpendicular to diameter a. From these volumes, tumor growth curves were constructed. In cases of successful treatment, 100 days with no recurrence was considered as cure. In the case of recurrence, the animal was considered incurable and humanely euthanized when the tumor diameter was between 1.5 and 2 cm. Survival time extended from the time of first treatment to 100 days (successful treatments) or to killing (recurrences).
In vivo treatments
All in vivo experiments were approved by the ethics committee of University College Cork. When tumors reached approximately 100 mm 3 in volume (5-7 mm major diameter), mice were randomly divided into experimental groups and subjected to specific experimental protocols. Mice were anesthetized during all treatments by intraperitoneal administration of 200 mg xylazine and 2 mg ketamine. For DNA delivery, a custom-designed applicator with two needles 4 mm apart was used, with both needles placed through the skin central to the tumor. Tumors were injected between electrode needles with 1 mg plasmid DNA in sterile injectable saline per mm 3 tumor in an injection volume equal to the volume of the tumor unless otherwise noted. After 80 s, square-wave pulses (1200 V/cm 100 ms Â 1 and 120 V/cm 20 ms, eight pulses) were administered in sequence using a custom-designed pulse generator (CythorLab, Aditus, Lund, Sweden). In all cases, a drop in impedance measurement was taken as evidence for successful tissue cell poration. In vivo luciferase activity from pGL3-treated tumors was analyzed 48 h posttransfection as follows: 80 ml of 30 mg/ml firefly luciferin was injected intratumorally. Mice were anesthetized as before. Ten minutes after luciferin injection, live anesthetized mice were imaged for 1 min using an intensified CCD camera (IVIS Imaging System, Xenogen).
Induction of hepatic metastases
Mice were anesthetized as described. The left flank was shaved and a 1-1.5 cm incision made over the spleen. The abdominal muscles were divided and the peritoneum opened. Two 5/0 vicryl ligatures (Promed, Dublin, Ireland) were tied (gently, to avoid lacerating the parenchyma) around the spleen at its central portion, Figure 1 Plasmid used in this study. Schematic representation of coding regions of pGT141 plasmid. The DNA encoding GM-CSF and B7-1 (CD80) transcriptionally controlled by the indicated promoters is shown. The plasmid backbone pMG lacks CD80 and GM-CSF cDNA. Cleavage sites for restriction enzymes used in the construction of monocistronic plasmids are indicated.
Tumor electroporation with GM-CSF, B7-1 plasmid CG Collins et al 0.5 cm apart, and the spleen divided between them. The two halves of the spleen were thus separate from each other but both still in contact with the portal circulation. A total of 1 Â 10 6 JBS cells, suspended in 100 ml DMEM, were injected into one half of the spleen and allowed 2 min to reach the portal circulation, before the hilar vessels were ligated and that portion of the spleen excised, leaving the mouse with half of the original spleen. Mass closure of peritoneum, muscles and skin was performed using 4/0 prolene sutures (Promed). Animals were then observed for development of disease or culled at set time points for histological analysis of the liver.
In vitro cytotoxicity assay To assay CTL activity against JBS cells, splenocytes were harvested from mice responding to GM-CSF/B7-1 treatment and resistant to tumor growth on rechallenge with JBS. The spleen was harvested and in order to induce tumor-specific lymphocytes, 2 Â 10 6 splenocytes were incubated with 2 Â 10 5 mitomycin C-treated JBS cells in the presence of 25 IU/ml rmIL-2 (Sigma) for 5 days. Lymphoid cells were then harvested, washed three times in serum-free medium and applied as effectors at various effector:target (E:T) ratios (100:1, 20:1, 1:1), with 2 Â 10 4 wild-type JBS cells as targets. Cells were incubated overnight in 96-well round-bottomed plates to allow target cell killing. Wells were then washed five times with PBS to eliminate non-adherent (dead target and all effector cells). The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was used to quantify remaining living cells. MTT working solution (final concentration of 0.45 mg/ml) was added to each well and the cultures were incubated for 4 h at 371C in a humidified 5% CO 2 atmosphere. Culture medium was then removed from each well and the precipitate dissolved with 150 ml of dimethyl sulfoxide (Sigma) for 10 min. The absorbance value of each well was measured by a Softmax-Pro microculture plate reader (Molecular Devices, Biosciences, Dublin, Ireland) at a 570 nm wavelength. Percentage cytotoxicity was calculated using a standard formula. All MTT experiments were performed in triplicate wells and repeated three times. Results of representative experiments are given as the mean7 standard deviation (s.d.) and of multiple experiments as the mean7standard error (s.e.).
In vivo cytotoxicity assay and adoptive transfer of lymphocytes to tumor-bearing mice The development of an immune-mediated antitumoral activity following treatment was tested by a modified Winn assay. 21 The procedure of Winn et al. was utilized as follows: mice (six/group) received injections of a mixture of JBS cells and splenocytes from either pGT141-cured mice or naı¨ve mice. Splenocytes were taken 100 days after tumor regression from 'cured' mice for use in Winn assays. Splenocytes were mixed with tumor cells and injected s.c. in a proportion of 50:1 (10 8 spleen cells to 2 Â 10 6 JBS cells). Mice were then monitored on alternate days for tumor development. For assessment of effects of adoptive transfer of lymphocytes on pre-existing tumors, modified Winn assays were performed on groups of mice that were challenged 7 days previously with a tumorigenic dose of JBS cells, by which time tumors were palpable (of average volume 28 mm 3 ) and taken to be vascularized.
Histological analysis
Tumors and livers were removed from mice at necropsy. Tissues were fixed in 10% v/v buffered formalin and embedded in paraffin. Serial sections were cut at 5 mm and mounted on slides. For hematoxylin and eosin (H&E) analysis, sections were stained with H&E using standard procedures. The TUNEL (transferase-mediated dUTP nick end-labelling) method was used to detect apoptotic cells in tissue. Sections were de-paraffinized, rehydrated and made permeable by incubating sections with proteinase K (2 mg/ml) (Roche, Fannin Healthcare, Dublin, Ireland) for 15 min at 371C. Negative controls were included by omitting the labelling buffer. Positive controls were obtained by digestion of the sections with deoxyribonuclease I for 10 min at room temperature before the detection procedure. Images were collected using an Olympus BX51 microscope with either a Â 10 or Â 40 objective ( Â 100 or Â 400 magnification, respectively) coupled with an Olympus DP70 digital camera (Mason Technologies, Dublin, Ireland).
Statistical analysis
The primary outcome variable of the statistical analyses was the tumor volume in each mouse measured at each time point. The principal explanatory variables were the different treatment groups. Tumor volume was analyzed as continuous. Treatment groups were analyzed as categorical variables. At each time point, either one-way ANOVA or a two sampled t-test was used to compare mean tumor volume within each treatment group depending on the number of groups being compared. Microsoft Excel 10.0 (Microsoft) and SPSS Version 10.0 (SPSS Inc., Chicago, IL) were used to manage and analyze data. Statistical significance was defined at the standard 5% level.
Results
Plasmid functionality and growth of stable cell lines in mice
In vitro GM-CSF secretion and B7-1 cell surface expression was confirmed from JBS cells transfected with pGT141 (JBS141), whereas no expression was observed in pMG-transfected JBS (JBSPMG) (data not shown). JBS141 and JBSPMG were injected into the flank of Balb/C mice. The resultant tumor growth curves indicated that the presence of pGT141 had a significant effect on tumor growth in vivo. The transfected cells retained the ability to form solid vascularized tumors of a uniform average volume of 88 mm 3 , followed by spontaneous regression of tumors in 100% of animals ( Figure 2 
In vivo tumor transfection studies
Following results of tumor growth of pre-transfected cell lines, wild-type JBS tumors were induced in mice, and upon reaching an average 100 mm 3 were electroporated with the plasmids of interest (pGT141 or pMG). The minimum size at which tumors could be treated was limited to 80 mm 3 by the needles employed to administer electroporation. A parallel group of mice was electroporated with 100 mg luciferase coding pGL3 plasmid, and successful plasmid transfection and gene expression determined at 48 h post-treatment using whole body imaging (Figure 3a) . Reporter gene expression was detected in all tumors (n ¼ 7) albeit with significant intertumoral variability (luminescenceÀmean total flux ¼ 1.01 Â 10 4 p/s, s.e. ¼ 4.03 Â 10 3 p/s). Tumors were also removed from killed sample mice at this time, and ex vivo ELISA analysis of tumor tissue detected GM-CSF only in pGT141-transfected tumor lysate at 88 pg/mg tissue.
Resulting growth curves demonstrated that the electroporation in vivo of pGT141 significantly reduced the average growth rate of tumors (Figure 3a) , with 60% treated tumors completely and permanently regressing (Figure 3b ). This average 60% cure rate was consistent throughout several treatment groups, with complete tumor regression occurring in 54/90 mice (60%) following this therapy. Tumor plasmid injection in the absence of electroporation had no significant effect on tumor growth, nor did electroporation alone. Growth of nonresponding tumors was similar to that of pMG-treated and untreated tumors, with a temporary pause after transfection, which resulted in an increase in overall survival times (mean ¼ 25 days compared with 32 days, P ¼ 0.003). Tumors were also removed from killed sample mice at various time points following treatment, and H&E and TUNEL analyses indicated cell death by apoptosis only in tumors receiving pGT141 (Figure 4) .
In athymic nude mice, immunogene therapy had no effect on JBS tumor growth, demonstrating the necessity for T-lymphocyte function in the elimination of tumor containment (data not shown).
Treatment produces a long-term tumor-specific response 'Cured' mice were rechallenged to assess for an antitumoral immunological response. Mice were injected s.c. on the opposite flank to the original tumor challenge, with tumorigenic doses of the same tumor type (JBS) or another tumor type (CT26) 30 days following tumor regression. All of the JBS challenged mice remained tumor free for 100 days, whereas 100% of CT26 challenged mice succumbed to their disease (Figure 3d ). This demonstrated that treatment induces an antigenspecific immune response giving resistance to the same tumor cell line but not to a previously unexposed tumor cell line (CT26). With previously 'JBS cured' mice, CT26 was seen to grow at the same rate as in naı¨ve mice.
Effect of individual genes on tumor growth
To assess the effect of the individual genes (GM-CSF or B7-1) on the growth rate of the JBS fibrosarcoma, plasmids were electroporated into tumors using the described procedure. pGT141 and pMG were used as controls. Tumors that received both GM-CSF and B7-1 had a significantly reduced tumor growth compared with either GM-CSF or B7-1 alone ( Figure 5 ). Animal survival (Figure 5b ) confirmed the superior effect of the presence of both genes; however, it is notable that no cures were obtained in the GM-CSF-treated group (0% survival), whereas survival of the mice electroporated with B7-1 was 38%, suggesting that the presence of B7-1 may be critical for immune targeting.
Local treatment of subcutaneous tumor is effective in ablating growth of established distal tumors
To further demonstrate the systemic nature of responses to tumors arising from this treatment, either JBS or CT26 hepatic tumors were induced in groups (n ¼ 6) of 'cured' and naı¨ve mice as described in Materials and methods. Livers were removed from mice at necropsy, at various time points following treatment, and examined for the presence of metastases. All naı¨ve animals grew liver tumors, as visualized macroscopically and histologically, and required culling by day 15 (data not shown). All 'cured' mice receiving CT26 challenge also grew liver metastases, whereas none of the 'cured' mice receiving JBS challenge formed liver tumors.
To mimic a minimal residual disease tumor model, groups of mice received s.c. JBS tumors, followed 7 days later by hepatic JBS tumors. S.c. tumors, with controls, were treated as before on day 11 following s.c. challenge, and s.c. tumor growth followed. Five days later, mice were divided into groups according to s.c. tumor growth (regressing and non-regressing). Mice were killed at various time points; the livers were removed and examined for the presence of tumors. Figure 6 and Table 1 demonstrate that liver tumors were absent in 100% mice where s.c. tumor regression occurred. In mice where the s.c. tumor did not regress, liver tumor was either absent Tumor electroporation with GM-CSF, B7-1 plasmid CG Collins et al (2/7) or liver weight was statistically significantly less than that in animals that did not receive GM-CSF/B7-1 genes (P ¼ 0.001) ( Table 1 ). All control animals developed progressive hepatic metastases.
In vitro cytotoxicity
The cytotoxic activities of treated mouse lymphocytes against JBS were assessed. Spleen cells harvested from mice responding to GM-CSF/B7-1 treatment and naı¨ve mice were used to assess the in vitro CTL responses to JBS. Using the MTT-based assay as described in Materials and methods, it was determined that the cytolytic activity of splenic T lymphocytes against JBS cells was significantly greater in pGT141-treated mice than in naı¨ve mice (Figure 7a) . These results correspond with the observed systemic enhanced immunity in vivo.
In vivo cytotoxicity and adoptive transfer of lymphocytes The possible development of an immune-mediated antitumoral activity following pGT141 electroporation was also tested by the Winn assay, 21 where groups of mice Tumor electroporation with GM-CSF, B7-1 plasmid CG Collins et al received injections of a mixture of JBS cells and splenocytes from either pGT141-treated mice or naı¨ve mice. All mice receiving splenocytes from 'cured' mice failed to grow tumors, whereas JBS tumors developed in all control animals receiving splenocytes from naı¨ve mice (Figure 7b ). Furthermore, this effect was sustained with all surviving mice being resistant to a further JBS tumor challenge. This would suggest adoptive transfer to naı¨ve mice of a specific antitumor immune response conferring resistance to further tumor challenge.
Adoptive transfer of lymphocytes to tumor-bearing mice Having determined that splenocytes derived from 'cured' animals prevent tumor establishment, we set out to assess the effects of transfer of these cells to mice bearing palpable, vascularized tumors. Modified Winn assays were performed, as described, on groups of mice in which s.c. tumors were induced 7 days previously with a tumorigenic dose of JBS cells, by which time tumors were palpable (of average volume 28 mm 3 ) and taken to be vascularized. Regression of the initial tumor occurred in five of the 10 mice receiving 'cured' splenocytes, indicating transfer of efficient immunological recognition of and response to JBS antigen(s) capable of clearing the existing tumor burden. No effect on primary tumor growth was observed in mice receiving naı¨ve splenocytes (Figure 7c ).
Discussion
In this study, we demonstrate that local gene therapy of a solid tumor by the electroporation delivery of a plasmid coding for two immunogenes, GM-CSF and B7-1, resulted in the regression of the majority of the cancers and in the establishment of potent, durable, specific antitumor responses. Furthermore, this study shows that the intratumoral gene therapy resulted in systemic responses that were inhibitory of metastatic growth. Although systemic responses to tumors are usual (concomitant immunity), in this model they were ineffectual against metastatic development when compared with the potency of those induced by genetic therapy. This suggests that this form of therapy could be effective in a neo adjuvant setting against minimal residual disease.
The GM-CSF and B7-1 combination of genes has previously been used successfully to induce powerful antitumor vaccine responses. Extensive studies by Chong et al. 7 found that cell lines stably transfected in vitro to express GM-CSF and B7-1 had reduced tumorigenicity and induced a tumor-specific systemic protection against rechallenge. In that particular model, transgene expression and immune recruitment would be operational from the time of tumor induction and before tumorigenesis. Our studies extend these observations to a clinically applicable in vivo treatment. Electroporation-mediated delivery of the immunogenes into growing solid tumors resulted in gene expression in the growing tumor cells, Tumor electroporation with GM-CSF, B7-1 plasmid CG Collins et al induction of antitumor immune responses to a previously non-immunogenic tumor, elimination of solid tumor masses, inhibition of concomitant metastatic growth and induction of a durable specific and effective antitumor immunity. It is expected that the environment of the growing tumor provides a robust challenge to the immunogene therapy. In contrast to tumors grown from stably transfected cell lines, the immunogene is not uniformly distributed in the tumor mass and is introduced later in the tumor immune relationship where tolerogenic mechanisms are already established and where the tumor is populated by T-regulatory cells. 22 We have demonstrated that T-regulatory cells are present in the tumor at the time of treatment (data not shown), and thus local immune suppression mediated by Treg is overcome by this in vivo immunogene therapy.
Consistently, in all experiments, we found that in 40% of mice the responses of the primary tumors to immunogene therapy were partial and temporary. Although the cause of this local therapeutic failure is not evident, results from the JBS hepatic tumor model suggest that even in mice where the primary tumor was unresponsive, there was at least some degree of gene expression, which indeed did induce a concomitant immune response that was effective against micrometastases and was not evident in the control animals. It may be that a minimal threshold of GM-CSF and B7-1, relative to tumor size, is necessary for this system to be effective and that the degree of gene expression and its duration and intratumoral distribution could be important. Luciferase transfection experiments demonstrated that all tumors were transfected but with greater than 20-fold differences observed between tumors. In our electroporation treatment, it is likely that a large portion, but not all, of the tumor is transfected. This could be due to variations in tumor consistency, which might alter the intratumoral voltage characteristics and distribution of the injected DNA solution. Furthermore, regional variation in cell mitotic rates would affect plasmid nuclear uptake and subsequent gene expression. In an attempt to maximize transfection efficiency, we used intratumoral needle electrodes and saturated the tumor with DNA solution. Ex vivo experiments and electric field modelling indicate a pattern of cell permeabilization surrounding the needle electrodes that would account for the majority of the tumor area being subjected to permeabilization strength voltages. This electrode configuration is also consistently effective when used in electroporation chemotherapy protocols with bleomycin. 23 It is unlikely that there is a requirement for transfection of every tumor cell, as the mechanism of tumor regression is immune mediated, whereby targeting of non-transfected tumor cells is achieved after the gene therapy-induced immune sensitization.
It is also possible that non-integrated transgenes are silenced in tumor tissue and that duration of gene expression would be a function of gene copy number and the promoter silencing capability of the cancer cell. Promoters of viral origin such as those used in pGT141 have been shown to be silenced over time (as soon as 48 h post-transfection) in tumor and normal tissues -most likely owing to prokaryotic DNA methylation. Using in vivo imaging, we have found that CMV-driven luciferase expression in JBS diminishes after 9 days (data not shown). It is also possible that the induced antitumor effector responses may be attenuated by T-regulatory cells within the growing cancer and that immunogene therapy alone might be inadequate in larger tumors. Yu et al. have shown a selective accumulation of CD4 þ CD25 þ cells inside tumors, increasing with and permitting tumor growth, while a concomitant immunity remained evident at systemic levels. 24 Although we did select and randomize mice for study with tumors that had an average size of 100 mm 3 , it is possible that coexistence of small variations of tumor burden, degree of Treg infiltrate and level of gene expression determined the efficacy of immune containment of the tumor mass. Future studies are necessary to address the specific requirements for successful immunogene therapy of different solid tumors as it is likely that the therapeutic protocol will need Figure 5 Effects of individual genes on tumor growth. Growth (a) and survival (b) curves for tumors receiving either GM-CSF or B7-1 compared with the combination of GM-CSF and B7-1 (pGT141) and the blank plasmid (pMG). It can be seen that receiving both GM-CSF and B7-1 has a significantly reduced tumor growth compared with either GM-CSF or B7-1 alone (* indicates significance).
Tumor electroporation with GM-CSF, B7-1 plasmid CG Collins et al adaptation to tumor type. We have not found this protocol to be effective when treating CT-26 tumors. The electro-gene therapy protocol appears to be safe and non-toxic. All the mice remained healthy throughout the course of the experiments and there were no treatment-related deaths. This suggests that electroporation of the solid tumors is not unduly traumatic and that the GM-CSF produced by the tumors did not induce systemic toxicity. This is in keeping with the observations of Heller et al., 5 who found that the level of GM-CSF resulting from delivered gene, while increased within the tumor, was not measurable in peripheral blood and did not induce systemic toxicity. It is also noteworthy that on observation of the mice for greater than 3 months after eradication of the tumors, there was no evidence of autoimmune disease, suggesting that, in this model, at least immune clearance of bulky tumors could be achieved while maintaining autoimmune control.
This treatment could be applied clinically, particularly to those patients with cancers that are accessible transcutaneously and are recalcitrant to conventional therapies. The safety of electroporation as a part of a clinical therapy has been validated in several studies of electrochemotherapy of cancer in humans in Europe and the USA. It is also unlikely that in the clinical setting, GM-CSF production would achieve systemic levels equivalent to those used in clinical bone marrow therapies. Although the precise mechanisms of action of the gene therapy products in the tumor region have yet to be studied, there is strong evidence that their cumulative effects result in potent, durable and specific antitumor responses. It is also likely that part of the effect is unrelated to gene expression; bacterial CpG sequences present on non-internalized plasmid DNA may be in part responsible for initial APC stimulation via Toll-like receptor 9 and subsequent CTL recruitment. Indeed, this might explain the slight improvement in survival from treatment with pMG observed in Figure 3c .
This treatment would be individual to the host and the tumor at any stage of its development and could provide a convenient alternative to vaccination and ex vivo cellbased therapies. This strategy of immunogene therapy of the primary tumor could also be used in a neo-adjuvant setting against minimal residual disease, as it is likely that the disseminated micrometastases share the same antigen spectrum as the primary tumor. We have previously reported that patients with colon cancer Dukes' stage B who have a strong immune reaction within their resected tumors have improved survival prospects and clear micrometastases from their bone marrow. 25 Clearance of the primary tumor mass by the gene therapy does not appear to be a prerequisite for control of distal tumors, as in the hepatic model used in this study, liver tumors did not emerge even in those cases where the treated primary tumors did not regress.
We conclude that immunogene therapy of solid tumors by electroporation results in the development of potent, durable, specific antitumor immunologic responses that Splenocytes from either pGT141 'cured' or naïve mice were adoptively transferred as for Winn-type assays to mice already bearing JBS tumors of average volume 28 mm 3 . Regression of the initial tumor occurred in five of the 10 mice receiving 'cured' splenocytes. No effect on primary tumor growth was observed in mice receiving naïve splenocytes. In the non-responding tumors (5/10), growth curves were similar to controls.
Tumor electroporation with GM-CSF, B7-1 plasmid CG Collins et al
